This Month
1
1 upcoming, 0 historical review dates.
Calendar
Immovable lifecycle review calendar
0
0 post-mortem tasks pending in tasks/pending/
Completed
0
Review dates with post-mortems already ingested.
Selected Date
22 Sept 2026
Sun Pharmaceutical Industries
SUNPHARMA • ACTIVE • value fundamental
Hold 48 days • Review / exit 22 Sept 2026
-2.04% Post-mortem pending
Sun Pharmaceutical Industries
SUNPHARMA • ACTIVE • value fundamental
Hold 48 days • Review / exit 22 Sept 2026
Sun Pharma has fresh Q1 FY27 evidence with net profit up about 27% YoY and sales up about 10%, while the stock is above its 50-DMA and 200-DMA after a controlled pullback from a recent 52-week high. The pick adds liquid pharma exposure, but the stop must respect the post-results support zone because Q1 revenue missed some estimates.
Prices
Entry: ₹1,939.80
Current: ₹1,900.20
P&L: -2.04%
Hold Plan
Target hold: 48 days
Held so far: 30 days
Review / exit: 22 Sept 2026
18 days left
Assumptions
A1: The stock should hold above Rs 1,880 after the post-results pullback.
A2: The MOFSL innovation-pipeline upside case remains active through the review window.
Bought 5 Aug 2026
Accepted from analysis task analysis-2026-06-15-0830
Confirmed and held 13 Aug 2026
At Rs 1,941 (flat vs entry Rs 1,939.8); Q1 PAT +27% with Organon acquisition on track and Motilal Oswal Buy (Rs 2,310) support the Rs 2,140 target; stock sits ~8% above its 200-DMA (Rs 1,798).
Flagged for a closer look 18 Aug 2026
₹1,881 vs entry ₹1,939.8 (-3.0%); Aug 17 fall (~-2.5%) made it a worst-in-Nifty name - now below the ~₹1,902 50-DMA though above the ₹1,798 200-DMA and the ₹1,823 stop; monitor the post-results support zone ~₹1,850.
Back to normal 21 Aug 2026
At ₹1,898.5 vs entry ₹1,939.8 (-2.1%), the stock was on WATCH after Q1 revenue missed; it has since recovered from ~₹1,795 to ~₹1,900 (top NSE gainer on Aug 19, +1.3%) and the Organon deal remains on track, so upgrade back to HOLD with the ₹2,140 target intact.
No corporate events attached.